Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3957820 | 0.85 | CYP3A4 (0.41) | CYP3A4CYP1A2CYP2C9 | |
| SCHEMBL4032084 | 0.81 | CYP3A4 (0.53) | CYP3A4CYP1A2CYP2C9 | |
| SCHEMBL4038404 | 0.81 | CYP3A4 (0.53) | CYP3A4CYP1A2CYP2C9 | |
| SCHEMBL4336874 | 0.78 | CYP3A4 (0.50) | CYP3A4CYP1A2CYP2C9 | |
| SCHEMBL13647531 | 0.77 | CYP3A4 (0.53) | CYP3A4CYP1A2CYP2C9 | |
| SCHEMBL4038742 | 0.74 | CYP3A4 (0.51) | CYP3A4 | |
| SCHEMBL5353655 | 0.74 | CYP3A4 (0.51) | CYP3A4 | |
| SCHEMBL6281798 | 0.74 | CYP3A4 (0.46) | CYP3A4CYP1A2CYP2C9 | |
| SCHEMBL4034780 | 0.73 | CYP3A4 (0.47) | CYP3A4CYP1A2CYP2C9 | |
| SCHEMBL3956635 | 0.73 | CYP3A4 (0.63) | CYP3A4CYP1A2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7601721-B2 | Substituted heterocyclic compounds | GILEAD PALO ALTO, INC. (US) | 2009-10-13 | — | — | US | disclosed |
| US-20080070927-A1 | Substituted Heterocyclic Compounds | ZABLOCKI JEFF | 2008-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070927-A1 | Substituted Heterocyclic Compounds | KCNJ2, KCNH1, KCNJ1 | CYP3A4 1454/4885CYP1A2 1155/4885CYP2C9 2053/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.